基于肼基导向的C-H键活化合成含氮杂环化合物

李 嘉琪1, 刘景 林*1, 李 　贺2
1、内蒙古民族大学化学与材料学院
2、内蒙古自治区天然产物化学及功能分子合成重点实验室

摘要


含氮杂环化合物是多种天然产物、生物活性分子和药物的核心骨架，过渡金属催化肼基导向的C-H键活
化反应是合成含氮杂环化合物的有效方法之一.本文按照构筑的含氮杂环大小，分别综述了过渡金属催化肼基导向
C-H键活化反应合成含氮杂环化合物的重要研究进展，对底物适用范围和反应机理等进行了详细论述，并就该领域
的局限性和未来的发展前景进行了总结和展望.

关键词


过渡金属催化；肼基；C-H活化；杂环化合物

全文:

PDF


参考


[1]For selected reviews: (a)Tamatam, R.; Dong, Y. S.

Molecules. 2023, 28, 3227.

(b)Biplob Borah, L.; Raju Chowhan. RSC Adv. 2021, 11,

37325.

(c)Yang, Z. X.; Yu, J. T.; Pan, C. D. Org. Biomol. Chem.

2022, 20, 7746.

[2]For selected reviews:(a)Liu, X. H.; Shen, Z. H.;

Wang, Q. Current Organic Chemistry, 2017, 21, 1626-1650.

(b)Shan,Y. Y., Su, L.; Zhao, Z. H. Adv. Synth. Catal.

2021, 363, 906-923.

(c)Swami, S.; Sahu, S. N.; Shrivastava, R. RSC Adv.,

2021, 11, 39058.

[3]For selected reviews:(a)Cao, C. K.; Sheng, J. Y.;

Chen, C. Synthesis. 2017, 49, 5081-5092.

(b)Łowicki, D.; Przybylski, P. European Journal of Medicinal Chemistry. 2022, 235, 114303.

(c)Arshadi, S.; Vessally, E.; Edjlali, L. Beilstein. J. Org.

Chem. 2017, 13, 625-638.

[4]For selected reviews:(a)Tabasso, S.; Gaudino, E. C.;

Cravotto, G. Molecules. 2019, 24, 288.

(b)Youn, S. W.; Cho, C. G. Org. Biomol. Chem., 2021,

19, 5028.

(c)Jeong, S.; Joo, J. M. Acc. Chem. Res. 2021, 54,

4518-4529.

[5]For selected reviews:(a)Sahoo, S. R.; Dutta, S.; Maiti, D. Chem. Commun. 2021, 57, 11885.

(b)Qiao, S. J.; Deng, W. B.;Yang, Y. Org. Biomol.

Chem. 2022, 20, 6275.

[6]For selected reviews:(a)Ghosh, S.; Mondal, S.; Hajra,

A. Adv. Synth. Catal. 2020, 362, 3768-3794.

(b)Liu, X.; Huang, Y.; Meng, X. Synlett. 2019, 30, A-K.

[7]Ghosh, D.; Ghosh, S.; Ghosh, A. Chem. Commun.

2022, 58, 4435.

[8]Mal, S.; Mahapatra, M.; Paidesetty, S. K. Drug Dev

Res. 2022, 83,1469-1504.

[9]For selected reviews:(a)Wan, Y. C.; He, S. Z.; Tang, Z.

L. Anti-Cancer Agents in Medicinal Chemistry. 2018, 18, 1-7.

(b)Meng, G.; Yang, T.; Liu, Y. Organic Preparations and

Procedures International. 2011, 43, 354-359.

[10]Yadav, P.; Velmurugan, N.; Luscombe, C. K. Synthesis. 2023, 55, 1-26.

[11]Zhang, Y. H.; Liu, Z. X.; Yao, J. Z. Org. Biomol.

Chem. 2014, 12, 5469-5476.

[12]Yu, C. M.; Jiang, X. P.; She, Y. B. Chem. Commun.

2020, 56, 7415-7418.

[13]For selected reviews:(a)Caruso, A. Appl. Sci. 2023,

13, 4263.

(b)Zhang, B. S.; Zhao, S. Y.; Quan, Z. J. J. Org. Chem.

2023, 88, 1786-1795.

[14]Liu, J. L.; Liu, J. H., Li, H.J. Org. Chem.

[15]Tan, C.; Yang, S. J.; Zhao,D. H. Arabian Journal of

Chemistry. 2022, 15, 103756.

[16]Zhu,Y. Q.; Zhao, J. R.; Zhang, H. L. European Journal of Medicinal Chemistry. 2021. 223, 113665.

[17]Stypik, M.; Michałek, S.; Orłowska, N. Pharmaceuticals. 2022, 15, 927.

[18]Xu, D.; Xu, Z. Current Topics in Medicinal Chemistry, 2020, 20, 1938-1949.

[19]Horrocks, P.; Denman, L.; Devine, O. Bioorg. Med.

Chem. Lett. 2012, 22, 1770-1773.

[20]Reddy, G. S.; Pal, M. Current Medicinal Chemistry,

2021, 28, 4531-4568.

[21]Ölgen, S. Medicinal Chemistry, 2013, 13, 1700-

1708.

[22]Glorius, F.; Zhao, D. B.; Shi, Z. Z. Angew. Chem.

Int. Ed. 2013, 52, 12426-12429.

[23]Wang, B. Q., Liang, Y. J., Yu K. Chem. Commun.

2014, 50, 6130-6133.

[24](a)Feng, F.; Yuan, Y. H.; Tian, M. Z. Elsevier. Ltds.

2017, 141,363-365.

(b)Atef M. Amer. Monatshefte fuÈr Chemie. 2001, 132,

859-870.

[25]Hou, W.; Xu, H. T.; Su, L. Org.Biomol.Chem. 2018,

16, 7236-7244.

[26]Zhu, J.; Song, C., Yang, C. Org. Lett. 2016, 18,

4510-4513.




DOI: http://dx.doi.org/10.12361/2661-3654-06-08-137221

Refbacks

  • 当前没有refback。